Sweeney & Michel LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,339 shares of the company’s stock after purchasing an additional 1,212 shares during the quarter. Johnson & Johnson comprises 2.8% of Sweeney & Michel LLC’s investment portfolio, making the stock its 9th largest holding. Sweeney & Michel LLC’s holdings in Johnson & Johnson were worth $5,427,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of JNJ. Rather & Kittrell Inc. boosted its stake in Johnson & Johnson by 2.0% in the 2nd quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock worth $481,000 after buying an additional 58 shares during the last quarter. Capital Square LLC boosted its stake in Johnson & Johnson by 1.4% in the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock worth $703,000 after buying an additional 58 shares during the last quarter. Wagner Wealth Management LLC boosted its stake in Johnson & Johnson by 1.3% in the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock worth $752,000 after buying an additional 59 shares during the last quarter. Chesapeake Wealth Management boosted its stake in Johnson & Johnson by 0.7% in the 2nd quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock worth $1,522,000 after buying an additional 60 shares during the last quarter. Finally, MTM Investment Management LLC boosted its stake in Johnson & Johnson by 0.5% in the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after buying an additional 61 shares during the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have recently commented on JNJ shares. Raymond James cut their price objective on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. Royal Bank of Canada started coverage on Johnson & Johnson in a report on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 price objective on the stock. Barclays raised their price objective on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Finally, Wells Fargo & Company dropped their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $149.79 on Monday. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $181.04. The business has a 50 day moving average price of $154.77 and a two-hundred day moving average price of $160.38. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a market cap of $360.59 billion, a PE ratio of 11.12, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.52 by $0.14. The company had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. Sell-side analysts expect that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be given a $1.19 dividend. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is 35.34%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- 3 Grocery Stocks That Are Proving They Are Still Essential
- DigitalOcean rises on AI-powered infrastructure service demand
- Investing in large cap stocks: Diving into big caps
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 11/13 – 11/17
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.